Trastuzumab-induced hepatotoxicity: A case report

Breast Care

Volumn 8, Issue 2, 2013, Pages 146-148

  Vucicevic, Darko ^a   Carey, Elizabeth J ^b   Karlin, Nina J ^a  

^a MAYO CLINIC   (United States)

^b Division of Hepatology   (United States)

Author keywords

Breast cancer; Hepatotoxicity; Liver toxicity; Trastuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERTAPENEM; ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR; TRASTUZUMAB; VANCOMYCIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FUNCTION TEST; LOADING DRUG DOSE; MASTITIS; MULTIPLE CYCLE TREATMENT; PATIENT PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; RADIATION DOSE; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT DURATION; CANCER CHEMOTHERAPY; DOPPLER FLOWMETRY; MEDICAL EXAMINATION; MIDDLE AGED; TRASTUZUMAB INDUCED HEPATOTOXICITY;

EID: 84878497486     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000346844     Document Type: Article

References (15)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300;
2. Erratum in CA Cancer J Clin 2011;61:133-134.
3. Daniele L, Sapino A: Anti-HER2 treatment and breast cancer: State of the art, recent patents, and new strategies. Recent Pat Anticancer Drug Discov 2009;4:9-18.
4. Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003;532:253-268.
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
7. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, HERA study team: 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
8. Lin A, Rugo HS: The role of trastuzumab in early stage breast cancer: Current data and treatment recommendations. Curr Treat Options Oncol 2007; 8:47-60.
9. Srinivasan S, Parsa V, Liu CY, Fontana JA: Trastuzumab-induced hepatotoxicity. Ann Pharmacother 2008;42:1497-1501.
10. Munoz A, Carrera S, Ferreiro J, de Lobera AR, Mane JM, Lopez-Vivanco G: Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer. Ann Oncol 2007;18:2045-2046.
11. Danan G, Benichou C: Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
12. Benichou C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-276.
13. Maria VA, Victorino RM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-669.
14. Hayashi PH: Causality assessment in drug-induced liver injury. Semin Liver Dis 2009;29:348-356.
15. Hunt CM: Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: A systematic review. Hepatology 2010;52:2216-2222.